Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

US Food and Drug Administration (FDA) approval

 of icotrokinra (Icotyde) for moderate to severe plaque psoriasis was announced for adults and adolescents aged 12 and older with a weight of at least 40 kg who are candidates for systemic therapy or phototherapy.

 interviewed Linda Stein Gold, MD, about icotrokinra’s recent FDA approval, the gaps this treatment fills for patients with 

, and the significance of the drug’s approval as first oral targeted peptide to selectively block the interleukin (IL)-23 receptor.

The introduction of this new mechanistic class to the psoriasis armamentarium was highlighted in this interview. The following Q&A with 

 transcribes the interview in its entirety:

As one of the investigators on the ICONIC program, what did you observe that you think practicing dermatologists should know when thinking about where this drug fits relative to agents they're already comfortable prescribing?

 I think we've had a big unmet need for our moderate to severe plaque psoriasis patients. We have great biologic agents, we have good topical agents, but the oral space really needed something that had very good efficacy, very good safety, and very good tolerability. So I think that this drug fills that need, and where we see efficacy that's similar to biologic agents, yet we still have the good safety and tolerability. I think that this fits in nicely for any patient that needs systemic therapy.

What does the efficacy and safety picture tell a dermatologist who is deciding whether to reach for icotrokinra after topical failure, or to reserve it for patients who have already tried a systemic agent?

When we look at the efficacy data, we see that this drug kicks in pretty rapidly. It was studied in in several phase three clinical trials against placebo, but it was also studied against deucravacitinib, prior to this drug, and this had the best efficacy for any of the oral drugs in that treatment space. What we see is the drug starts to kick in fairly rapidly.

We see a nice, deep slope, and there's good separation from the placebo, but also from deucravacitinib as early as Week Four. That continues over the 16 weeks, and we see up to about 70% of patients getting to clear or almost clear by Week Sixteen, and that continues through even the long term studies.

The approval includes adolescents aged 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. For pediatric dermatologists who manage patients right at that threshold, how do the trial data and experience inform the potential of this agent in pediatric populations?

The pediatric population who have moderate to severe psoriasis is a really important patient population. A lot of them would prefer an oral agent, and we need drugs that have been shown to be both safe and efficacious in the adolescent population. What we found was really good news. This drug actually performed even even better in the adolescence that it did in the adults, and it was equally well tolerated and a very good safety profile.

 What did you observe in the trial around adherence and caregiver involvement among adolescent participants that practicing pediatric providers should factor into their own counseling?

In the clinical trials, we asked the patients to take the medication once a day, generally in the morning after they wake up. For most people, it really fit in well with their activities of daily living. Some people take other pills, so they're used to taking a pill. For our adolescents, the idea that they didn't have to have a shot was good news for a lot of them. I think it's pretty easy, especially because it's a once daily dosing.

Based on what you saw in the trial population, what would you want a primary care clinician to take away about recognizing when a patient has outgrown what topicals can offer?

We tend to have treatment inertia. When it comes to our psoriasis patients, [let’s say] we put them on a topical medication. Maybe they're not doing so well, so maybe we think about another topical medication. We don't always progress to a systemic medication, probably, as quickly as we need to. So, for those patients who aren't getting a really good treatment efficacy with topical medication, it's a good idea to start thinking about a systemic medication. Icotrokinra is an oral peptide. It's targeting the IL-23 receptor.

This is a key receptor in the key pathway in the pathogenesis of psoriasis, and we understand this pathway really well. We've seen with this medication, it's easy to take. You just take it once a day, usually on the in the morning, on an empty stomach. We saw efficacy start to kick in within the first several weeks, and continued improvements over the primary endpoint, which was Week Sixteen, and continued efficacy, even in the long term. I think that this fulfills an unmet need. A lot of our patients would prefer an oral option, so now we have one that really has that triad of efficacy, safety, and tolerability.

 How would you encourage a primary care provider to re-open that conversation with a patient who previously said no to injectables and what from the trial gives you confidence that the oral route could change that dynamic?

We have to remember that psoriasis is a systemic disease and that there's systemic inflammation, especially for those patients who have moderate to severe plaque psoriasis. I tell my patients that I really want to treat them as a whole. I want to get the disease under control, but I really think that they need a systemic medication. This drug allows us to offer an oral agent that targets at the key inflammatory pathway that we understand is at the root of the pathogenesis of psoriasis. It's been shown to kick in pretty rapidly, really, within the first several weeks.

It's been shown to be superior not only to the placebo, but also against oral deucravacitinib, which was the highest efficacy drug that we had prior to the approval of icotrokinra. I'm I have good confidence, especially because it was studied in adolescence down to age twelve. So, I love the fact that we have a new option for our adolescents as well as our adults who are systemic candidates.

Where do you hope that any additional research goes for icotrokinra and its use among such patients?

I hope that we see continued research in psoriatic arthritis. I'd also love to see FDA approval for our younger patients. We know that the pediatric population psoriasis doesn't start at age twelve, and we can see it even younger. To have an oral option for our younger patients would be wonderful.

Campbell P. Icotrokinra, an Oral Il-23 Inhibitor, Receives FDA Approval for Psoriasis. HCPLive. March 18, 2026. Accessed March 20, 2026. 

https://www.hcplive.com/view/icotrokinra-receives-fda-approval-for-psoriasis

Johnson and Johnson. FDA approves ICOTYDE (icotrokinra), the first and only targeted oral peptide IL-23 receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis. Press release. Published March 18, 2026. Accessed March 20, 2026. 

https://www.jnj.com/media-center/press-releases

Articles

Icotrokinra (Icotyde) received FDA approval for moderate-to-severe plaque psoriasis in adults and adolescents ≥12 years weighing ≥40 kg who are candidates for systemic therapy or phototherapy. Positioned as the first oral targeted peptide selectively antagonizing the IL-23 receptor, it addresses an unmet need in the oral systemic space by pairing biologic-like efficacy with favorable safety and tolerability. Phase 3 data demonstrated rapid onset with separation from placebo and deucravacitinib by Week 4 and ~70% achieving clear/almost clear by Week 16, with durability long term.

In this Q&A, Linda Stein Gold, MD, shares her views on the clinical significance of icotrokinra's FDA approval and the data leading to this approval.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Q&A: Research Leading to FDA Approval of Icotrokinra for Psoriasis, With Linda Stein Gold, MD

Mark Taylor, MD, a consultant psychiatrist from The Edinburgh Practice and a professor in the school of medicine and dentistry at Griffith University.

GLP-1s Linked to Reduced Anxiety, Suicidality, With Mark Taylor, MD

New real-world evidence suggests GLP-1 receptor agonists may present mental health benefits in patients with type 2 diabetes, including reduced anxiety, 

“We’re not trying to say that GLP-1s are antidepressant or anti-anxiety drugs, even though they do cross the blood brain barrier and appear to have central effects, but in people with depression and anxiety, in people with type 2 diabetes, particularly, this is going to be a useful, dually effective therapeutic option,” said Mark Taylor, MD, a consultant psychiatrist from The Edinburgh Practice and a professor in the school of medicine and dentistry at Griffith University in Australia, in an interview with 

Taylor explained that he and his colleagues conducted the study to address prior safety concerns raised by the US Food and Drug Administration (FDA) regarding potential associations between GLP-1 therapies and suicidal ideation. In August 2024, a 

JAMA study suggested that semaglutide may be linked to increased suicidal ideation

 reported; 107 on semaglutide and 162 on liraglutide reported suicidal ideation or self-harm.

 The study only detected significant disproportionality for semaglutide-associated suicidal ideation, not with liraglutide.

The 2024 study led the FDA to investigate the link between GLP-1s and suicidal ideation.

 After months of evaluation, the agency did not find evidence that any GLP-1s cause suicidal thoughts or actions. The clinical trials show that only a small portion of participants experience suicidal ideation when on GLP-1s; suicidal ideation could be influenced by other factors.

Using nationwide Swedish registry data, investigators applied a within-individual study design, comparing periods when the same patient was receiving a GLP-1 receptor agonist versus periods without treatment.

 This approach helps reduce confounding by indication and selection bias, strengthening the validity of observed associations relative to traditional cohort analyses. As Taylor explained, each individual was their “own control.”

Across multiple real-world endpoints, including hospitalization, sick leave, self-harm, and suicide, the findings pointed toward consistent psychiatric benefit rather than harm. GLP-1 receptor agonist use was associated with reduced suicidality, countering earlier safety concerns.

Two outcomes stood out clinically: reductions in psychiatric-related sick leave and lower rates of suicidal behavior.

“Mental health is now pretty much the most common reason people take time off work for health,” he noted.

The analysis did not suggest a uniform class effect. Among individual agents, semaglutide demonstrated the most pronounced benefit, including an approximately 40% reduction in depression-related outcomes and a 42% reduction in hospitalization risk during treatment periods compared with nonuse.

“This is a powerful effect,” Taylor said. “Even as authors, we were surprised by the size of this effect.”

Other GLP-1 receptor agonists showed more modest or no effect. Liraglutide demonstrated intermediate benefit, while exenatide and dulaglutide were not associated with significant improvements in psychiatric outcomes.

“There's something going on there about semaglutide that makes it more potent than, for example, liraglutide,” Taylor said. “Now, I know a lot of folks in America are using Mounjaro or Zepbound. We didn't have enough patients in the database thus far to be able to bring that into the analysis.”

Taipale H, Taylor M, Markku Lähteenvuo, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Jari Tiihonen. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. The Lancet Psychiatry. 2026;13(4):327-335. 

doi:https://doi.org/10.1016/S2215-0366(26)00014-3

Derman C. Semaglutide Linked to Suicidal Ideation, New Study Reveals. HCPLive. Published August 23, 2024. Accessed March 20, 2026. 

https://www.hcplive.com/view/semaglutide-linked-to-suicidal-ideation-new-study-reveals

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. US Food & Drug Administration. Published January 13, 2026. Accessed March 20, 2026. 

https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type

Videos

New study finds GLP-1 RAs are associated with lower anxiety, suicidality, and sick leave in patients with diabetes and mental illness.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include the US Food and Drug Administration (FDA) approvals of icotrokinra (Icotyde) for moderate to severe plaque psoriasis in adults and pediatric patients ≥ 12 years of age weighing ≥ 40 kg who are candidates for systemic therapy or phototherapy, a new higher dose of semaglutide (Wegovy; Wegovy HD) injection 7.2 mg for weight loss in adults with obesity, and setmelanotide (Imcivree) for acquired hypothalamic obesity in adults and pediatric patients ≥ 4 years of age, as well as phase 3 data supporting retatrutide’s use in type 2 diabetes and finerenone’s role in nondiabetic chronic kidney disease.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of March 15, 2026—let’s jump in!

Icotrokinra, an Oral Il-23 Inhibitor, Receives FDA Approval for Psoriasis

On March 18, 2026, the FDA approved Johnson & Johnson’s icotrokinra (Icotyde) for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients ≥ 12 years of age weighing ≥ 40 kg who are candidates for systemic therapy or phototherapy. The approval marks the first for an oral targeted peptide selectively blocking the IL-23 receptor and introduces a new mechanistic class to the psoriasis treatment landscape backed by data from multiple trials in the phase 3 ICONIC program.

FDA Approves Higher Dose Semaglutide (Wegovy HD) Injection 7.2 mg for Obesity

On March 19, 2026, the FDA approved a new higher dose of Novo Nordisk’s semaglutide (Wegovy; Wegovy HD) injection 7.2 mg to be used along with a reduced calorie diet and increased physical activity to help adults with obesity lose weight and keep it off, provided they have tolerated the 2.4 mg dosage for ≥ 4 weeks and additional weight reduction is clinically indicated. The update supplements the existing semaglutide label, which also has distinct indications for semaglutide not offered by any other GLP-1 medication for weight loss.

FDA Approves Setmelanotide (Imcivree) for Acquired Hypothalamic Obesity

On March 19, 2026, the FDA approved an expanded indication for setmelanotide (Imcivree) to treat acquired hypothalamic obesity in adults and pediatric patients ≥ 4 years of age, making it the first and only FDA-approved therapy for this rare condition. The approval was based on data from the global, randomized, double-blind, placebo-controlled phase 3 TRANSCEND trial.

Retatrutide Delivers A1C Reduction, Weight Loss in Phase 3 TRANSCEND-T2D-1 Trial

On March 19, 2026, Eli Lilly and Company announced positive topline results from the phase 3 TRANSCEND-T2D-1 trial assessing the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise in people with type 2 diabetes and inadequate glycemic control. In the study, retatrutide met the primary and all key secondary endpoints, delivering superior A1C reduction and weight loss at 40 weeks compared to placebo, using both the efficacy and treatment-regimen estimands.

Finerenone Proves CKD Benefit Extends Beyond Diabetes in FIND-CKD

On March 16, 2026, Bayer announced the phase 3 FIND-CKD trial evaluating finerenone (Kerendia) in adult patients with nondiabetic chronic kidney disease met its primary endpoint, demonstrating a statistically significant improvement in eGFR slope versus placebo over 32 months. The company indicated it plans to submit the data to the FDA to seek a label expansion into this patient population, which would represent the broadest application of the agent to date across a CKD program now spanning > 20,000 patients in phase 3 trials.

Five near-term practice-shaping developments span dermatology, obesity medicine, endocrinology, and nephrology. FDA cleared icotrokinra, a first-in-class oral peptide IL‑23 receptor blocker, for moderate-to-severe plaque psoriasis in adults and adolescents meeting weight thresholds. Semaglutide received a higher 7.2 mg Wegovy HD dose option for adults with obesity after demonstrated tolerability at 2.4 mg. Setmelanotide gained the first approval for acquired hypothalamic obesity down to age 4. Retatrutide phase 3 data showed robust A1C and weight effects in type 2 diabetes. Finerenone improved eGFR slope in nondiabetic CKD, supporting label expansion.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new phase 3 data, in this week’s essential news roundup.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 03/15

David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado.

VIASKIN Peanut Patch Shows Strong Desensitization in Phase 3 Trial, With David Fleischer, MD

American Academy of Allergy, Asthma & Immunology (AAAAI)

 annual meeting in Philadelphia highlight the potential of the VIASKIN peanut patch, DBV Technologies’ epicutaneous immunotherapy containing 250 µg of peanut protein (1/1000th of 1 peanut kernel), as a practical, noninvasive option for children with 

. In the phase 3 VITESSE trial, the largest food allergy immunotherapy study to date, 82.8% of children receiving this peanut patch (VP250) increased their eliciting dose over 12 months.

“[With] that increase in eliciting dose, we know it's working,” David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado and global principal investigator of the VITESSE trial, told 

during the meeting. “Hopefully, it translates into protection from peanut allergic reactions.”

The study, conducted across 87 sites in Australia, Canada, Europe, and the US, sought to assess the efficacy and safety of VP250 in peanut-allergic children aged 4 – 7 years (baseline peanut eliciting dose ≤ 100 mg, psIgE > 0.7 kUA/L, and a skin prick test ≥ 6 mm). Children were randomized to receive either VP250 (n = 438; 60.5% males; mean age, 5.7 years) or placebo (n = 216; 65.7% males; mean age, 5.7 years).

VITESSE met its primary endpoint, with 46.3% of treated children (baseline eliciting dose of ≤ 30 mg) classified as responders compared with 14.7% in the placebo group (

 <.0001). Among children with a baseline eliciting dose of 100 mg, 43.1% were responders versus 14.6% in the placebo group. Beyond that primary outcome, most patients experienced measurable improvement: approximately 82.8% increased their eliciting dose over 12 months (versus 48% on placebo), and 60% improved by ≥ 2 dose levels during food challenge testing (versus 23.4% on placebo).

Unlike oral immunotherapy, which requires strict dosing protocols and activity restrictions, epicutaneous immunotherapy offers a simplified approach. The VIASKIN peanut patch delivers a small, fixed dose of allergen through the skin, without the need for dose escalation, dietary timing considerations, or limitations on exercise or illness.

Fleischer said the ease of use helps with adherence rates, which exceeded 96% in the trial. The safety profile remained favorable, with most treatment-emergent adverse events being mild, localized skin reactions. Serious adverse events were rare, and rates of treatment-related anaphylaxis were low.

Nearly 4 times as many children in the placebo arm experienced a decline in their eliciting dose over the study period compared to the patch arm (24% vs 6.4%). This finding reinforces the natural history of peanut allergy, which rarely resolves spontaneously.

“Only about 20% outgrow peanut allergy, and it shows that patients can get worse in the sense that their reaction threshold can lower over time,” Fleischer said. “It's all the importance in starting these therapies early…If only 1 in 5 outgrow it, we want to definitely try to protect these patients…we may be able to get them to the point where they can eat peanut[s] freely in their diet. That's the ultimate goal with these therapies.”

DBV Technologies has indicated plans to submit a Biologics License Application to the FDA in 2026.

Relevant disclosures for Fleischer include DBV Technologies, ARS Pharmaceuticals; UpToDate, Bryn Pharma, Aquestive Therapeutics, Nasus, and Genentech, and Grow Happy.

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting. DBV Technologies. Published February 28, 2026. Accessed March 20, 2026. 

https://dbv-technologies.com/press_releases/dbv-technologies-highlights-additional-data-from-successful-phase-3-vitesse-study-at-the-aaaai-2026-annual-meeting/

Phase 3 VITESSE data show VIASKIN peanut patch improves tolerance in most children, with high adherence and a favorable safety profile.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Takeaways on Icotrokinra and FDA approval and Psoriasis for Clinicians, With Linda Stein Gold, MD

Takeaways on Icotrokinra and Psoriasis for Clinicians, With Linda Stein Gold, MD

In the second part of her interview, Linda Stein Gold, MD, of Henry Ford Health System, touched on the gap between what topicals can realistically offer and when systemic therapy should enter the picture, how icotrokinra's oral profile can change the conversation among hesitant patients, and where she hopes the research goes following the 

 editorial team what primary care clinicians should take away about recognizing when a psoriasis patient has outgrown topical therapy, Stein Gold opened with a candid observation about a pattern she sees across the field: treatment inertia.

“We tend to have treatment inertia,” Stein Gold said. “When it comes to our psoriasis patients, we put them on a topical medication. Maybe they're not doing so well, so maybe we think about another topical medication, and we don't always progress to a systemic medication, probably as quickly as we need to first.”

Her message to primary care providers suggests when topical therapy is not delivering meaningful improvement, it may be time to consider a systemic option rather than cycling through more of the same. This framing set up Stein Gold’s response to the second question, which inquired as to how a clinician might reopen the systemic therapy conversation with a patient who has previously declined injectables.

Stein Gold's answer centered on what icotrokinra can provide as an oral agent. She pointed to the nature of psoriasis as a systemic disease driven by systemic inflammation, particularly in those living with moderate to severe plaque involvement, and that treating the whole patient means addressing that underlying pathway rather than managing surface symptoms alone.

Icotrokinra targets the interleukin (IL)-23 receptor, which she described as a key receptor in a pathway now well understood and recognized as central to the pathogenesis of psoriasis. For individuals who have resisted treatment escalation because of a fear of injections, Stein Gold pointed to icotrokinra's once-daily oral dosing on an empty stomach in the morning as removing the primary barrier.

Efficacy begins within the initial few weeks of use and builds through the primary 16-week endpoint and beyond. The trial data, Stein Gold noted, gives her genuine confidence in recommending the drug to systemic candidates across age cohorts. On the question of what she hopes comes next for icotrokinra research, Stein Gold was specific and forward-looking.

She expressed hope for continued investigation into psoriatic arthritis (PsA), described as the natural next step in research on icotrokinra given how central the IL-23 pathway is to both skin and joint disease. She also made a point of flagging the pediatric age gap. While the current FDA approval extends down to age 12, she noted psoriasis does not begin at 12 and describes an oral option for an even younger population as a meaningful advance.

Disclosures: Stein Gold has reported serving as an investigator, advisor, or speaker for AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB. AWA has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Arcutis, BMS, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Galderma, Incyte, Johnson & Johnson, Leo Pharma, Novartis, Parexel, Pfizer, Regeneron, Sanofi, Takeda, and UCB. RB is an advisory board member, consultant, speaker, investigator for, or received honoraria or grants from AbbVie, Alumis, Amgen, AnaptysBio, Arcutis, BMS/Celgene, Eli Lilly, Johnson & Johnson, LEO Pharma, Organon, Nimbus, Takeda, UCB, VentyxBio, Vyne, Xencor, and Zurabio, and is also an employee and shareholder of Innovaderm Research.

After the oral IL-23 inhibitor icotrokinra's (Icotyde) FDA approval, this interview covers what primary care clinicians should conclude.


Senior Allergy Dietitian at the Royal Children’s Hospital, Clinician-Scientist Fellow at MCRI & Honorary Senior Research Fellow at Melbourne University,

TreEAT: Clinical Implications, Screening Practices, and Next Steps, With Vicki McWilliam, MND, PhD

Hosts reveal how research, mentors, and clinic rotations spark a passion for skin disease and what makes dermatology unique.

ABCs in Dermatology: Our Hosts' Journeys to Dermatology

Deepak Bhatt, MD, MPH, MBA, discusses 4 trials to watch at the upcoming ACC.26.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

ACC.26 Late-Breakers to Watch, With Deepak Bhatt, MD, MPH, MBA

Balázs Szigeti, PhD, from the Translational Psychedelic Research Program at University of California San Francisco (UCSF)

Findings suggest psychedelics match antidepressants for symptom relief, with future research needed on real-world use and functional outcomes.

Psychedelics Expand Options, Not Efficacy, in Depression Care, With Balázs Szigeti, PhD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

GLP-1 discontinuation increases major adverse cardiovascular event risk in type 2 diabetes, highlighting the need for continuous therapy to sustain cardiometabolic benefit.

Atherosclerotic Cardiovascular Disease

GLP-1 Discontinuation Tied to Loss of Cardiovascular Protection  

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD Biologics in Practice: Exacerbation Reduction is No Longer Enough

Linda Stein Gold, MD, shares her perspective on the clinical significance of icotrokinra's FDA approval and what dermatologists need to know.

Key Points on Icotrokinra Following FDA Approval for Psoriasis, With Linda Stein Gold, MD

Experts discuss which outcome instruments are most useful in routine clinical practice and address how patients' tendency to underreport disease burden before experiencing effective treatment affects baseline severity assessment and escalation decision-making.

Video Series

Special Reports

Outcome Instruments in Practice and Baseline Underreporting in Untreated CSU

FDA clears setmelanotide for acquired hypothalamic obesity for ages 4 years and older, delivering 15.8% BMI drop in TRANSCEND.

FDA News

Experts review a phase 2 exploratory analysis of barzolvolimab in CSU, examining off-treatment efficacy at 28 weeks after the final dose, complete response rates, and quality-of-life outcomes among patients who achieved well-controlled disease after 52 weeks of treatment.

Latest News

Q&A: Research Leading to FDA Approval of Icotrokinra for Psoriasis, With Linda Stein Gold, MD

GLP-1s Linked to Reduced Anxiety, Suicidality, With Mark Taylor, MD

The HCPFive: Top News for Healthcare Providers from the Week of 03/15

VIASKIN Peanut Patch Shows Strong Desensitization in Phase 3 Trial, With David Fleischer, MD

Takeaways on Icotrokinra and Psoriasis for Clinicians, With Linda Stein Gold, MD